loader2
Partner With Us NRI

Lupin Ltd share Price Today

Company details

1,593.10
1,625.00
628.00
1,704.25
6M Return 42.78%
1Y Return 145.43%
Mkt Cap.(Cr) 73,617.27
Volume 865,183
Div Yield 0.25%
OI
-
OI Chg %
-
Volume 865,183

Open Free Trading Account Online with ICICIDIRECT

Incur '0' Brokerage upto ₹500
Beat on revenues but margins still below par…
About The Stock

    Lupin is a multinational pharma company engaged in manufacturing & marketing branded & generic formulations, APIs, biotech products as well as OTC medicines across multiple dosage forms & therapeutic categories.

    • It is the third largest generic player (by prescriptions) in the US with 166 generic products (market leader: 44 products; Top 3: 113 products) along with being sixth largest company in Indian pharmaceutical market
    • The company was recently going through a rough patch especially on the US generics front due to plant compliance issues besides margins pressure
Q4FY22

    Lupin’s revenues from US remained subdued while profitability was hampered due to high other expenses and impairment charges (₹ 127 crore)

    • Sales were up 2.6% YoY to ₹ 3883 crore
      • EBITDA was at ₹ 226.5 crore, down 68% YoY with margins at 5.8% mainly due to multiple factors namely - 1) higher input cost, 2) double digit price erosion in US, 3) losartan recalls, 4) Solosec litigation payment, 4) lower operating leverage and 5) higher freight cost
    • Adjusted loss of ₹ 525 crore vs. profit of ₹ 460 crore in Q4FY21

Click here for full recommendation

Research view on more stocks

Pharmaceuticals company Lupin announced Q3FY24 results:

Financial Performance

  • Sales: For Q3FY24, sales were reported at Rs 50,799 million, reflecting a QoQ growth of 2.8% from Rs 49,392 million and a YoY growth of 19.7% from Rs 42,446 million.
  • EBITDA: EBITDA for the quarter stood at Rs 10,673 million, an increase of 11.4% over Q2FY24's figure of Rs 9,582 million, and a substantial increase of 93.8% from Q3FY23's Rs 5,506 million.
  • EBITDA Margin: The EBITDA margin improved by 160 basis points to 21.0% in Q3FY24 from 19.4% in Q2FY24, and showed a significant rise from 13.0% in Q3FY23.
  • PBT: Profit before tax (PBT) for the quarter reached Rs 7,361 million, marking an increase of 16.9% from Q2FY24 and nearly a two-fold growth of 199.1% from Q3FY23.
  • Net Debt: Net debt as of December 31, 2023, stands at Rs 10,425 million with a low net debt-equity ratio of 0.07.
  • Capital Expenditure: The company reported capital expenditure of Rs 1,848 million for the quarter.

Operational Highlights

  • North America: Representing 37% of global sales, North America's sales were Rs 18,885 million, a modest growth from both the previous quarter and YoY figures.
  • India: Indian operations, contributing 34% to global sales, grew to Rs 17,251 million for the quarter, outpacing market growth and showcasing robust performance YoY.
  • Growth Markets: Comprising LATAM and APAC regions, sales were Rs 4,729 million, continuing an upward trajectory from the previous quarter and the same quarter of the previous year.
  • EMEA: Sales in the EMEA region, constituting 10% of global sales, reported Rs 5,170 million, indicating a strong upward movement compared to both Q2FY24 and Q3FY23.
  • Global API: Global API sales reported a slight QoQ increase and a minimal YoY decline, with sales reaching Rs 2,779 million.

Research and Development

  • Investment: R&D investments stood at Rs 3,567 million, accounting for 7.0% of the sales.
  • Approvals and Filings: Lupin received 14 ANDA approvals and launched 3 products in the U.S. during the quarter, bringing the total amount of generic products in the U.S. to 159.

Commenting on the results, Nilesh Gupta, Managing Director, Lupin, said, “We delivered our highest quarterly sales to date and crossed the 5,000 crore mark for the first time, driven by strong growth across geographies. The U.S. continues to do well driven by demand for both inline products and new launches, and the India business continues to grow ahead of the market with strong growth across our key therapies. This positive growth momentum coupled with cost optimization measures and operating leverage has helped us deliver solid performance”.

Result

 

 

View Other Company Results

Lupin Ltd shares SWOT Analysis

Strengths (15)

  • Rising Net Cash Flow and Cash from Operating activity
  • Company with high TTM EPS Growth
  • Strong Annual EPS Growth

Weakness (0)

Data not found

Opportunity (1)

  • Highest Recovery from 52 Week Low

Threats (2)

  • Promoter decreasing their shareholding
  • High PE (PE > 40)

Resistance and support

R1 1,630.2
R2 1,643.5
R3 1,662.1
Pivot

1,611.63

S1 1,598.3
S2 1,579.7
S3 1,566.4
EMA SMA
1,612.9
1,560.6
1,449.9
1,278.8
1,628.8
1,578.0
1,426.2
1,235.7
Delivery and volume
CLIENT NAME DEAL TYPE ACTION DATE AVG. PRICE QUANTITY EXCHANGE
SOCIETE GENERALE Block Purchase 2024-01-25 1449.2 747956 BSE
BNP PARIBAS ARBITRAGE Block Sell 2024-01-25 1449.2 747956 BSE
ISHARES CORE MSCI EMERGING MARKETS ETF Block Purchase 2022-11-14 747 228477 NSE
Name Category Shares
Manju D Gupta PROMOTER 0.85%
Lupin Investments Pvt Ltd PROMOTER 45.5%

OUR RESEARCH VIEW

Investment recommendation
Beat on revenues but margins still below par…
Call Date
11 May 2023
Entry Price 760.00
Target Price 740.00
Duration
12-18 Month

FINANCIALS

Sales
Operating Profit
Profit after Tax
Equity
Reserves and Surplus
Debt
Sales
Operating Profit
Profit after Tax
PE
Debt/Equity
P BV

Lupin Ltd Stocks COMPARISON

Financials( in Cr) Lupin Ltd Sun Pharmaceuticals Industries Ltd Cipla Ltd Dr Reddys Laboratories Ltd Zydus Lifesciences Ltd
Price 1,616.80 1,620.55 1,496.95 6,157.90 1,007.35
% Change 1.05 1.02 2.30 1.88 0.77
Mcap Cr 73,617.27 388,824.23 120,856.26 102,719.31 101,964.37
Revenue TTM Cr 16,641.66 43,885.68 15,790.60 24,669.70 17,237.40
Net Profit TTM Cr 447.69 8,560.84 2,513.47 4,507.30 1,997.30
PE TTM 40.66 41.13 29.93 19.30 30.34
1 Year Return 145.43 64.78 68.33 37.28 109.04
ROCE 5.70 16.79 14.76 25.99 16.25
ROE 3.64 16.46 10.66 21.21 14.05
INSIDER & INSTITUIONAL ACTIVITY

Equity Capital: 12,464.50 Cr FV: 2.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 30,755.54 31,723.05
LAST 3M 69,913.40 26,515.65
LAST 6M 130,081.93 60,306.69
LAST 12M 189,259.39 205,003.99
Lupin Limited - Sale / Purchase of shares

Mar 26, 2024 l NSE Announcement

Lupin Limited - Updates

Mar 22, 2024 l NSE Announcement

Lupin allots 52,041 equity shares under ESOP

Mar 21, 2024 l BSE Announcement

Date Action Type Ratio
Jul 14, 2023 Dividend 200
Jul 14, 2022 Dividend 200

Lupin Ltd Information

Stock PE (TTM)
40.66
Promoter Holding
47.04%
Book Value
290.5627
ROCE
5.7%
ROE
3.64%
Description
  • Lupin Ltd is in the Pharmaceuticals sector with the Market Capitalization of worth Rs. 44,266.89 crores, it is incorporated in the year 1968. It has a reported consolidated sales of Rs. 4,237.39 crores in June’2021. The company is also listed in the Bombay Stock Exchange (BSE) with the code 500257 and also listed in the National Stock Exchange (NSE) with the code LUPIN.

    Lupin Ltd is an Indian international pharmaceuticals company and is one of the largest generic pharmaceuticals companies globally based on revenue. The company primarily focuses on six areas, namely, paediatrics, cardiovascular, anti-infectives, diabetology, asthma, and anti- tuberculosis. Lupin has a global presence with operations spreading across 11 nations and 6 continents. Lupin has a team of over 1400 scientists working at Research 7 development headquarters located near Pune. Lupin ltd meets its corporate social responsibility through The Lupin Human Welfare & Research Foundation set up in 1988. The foundation mainly focuses on rural development projects that have reached over 3400 villages across eight states in the country to date. The promoters of the company own 46.84% of the stake in the company, Foreign Institutional Investors (FII) own 18.6%, Domestic Institutional Investors (DII) own 22.09% of the stake, and others (such as retail investors) hold the balance of 12.47%.

    In June 2021, quarterly net revenue was Rs. 3,314.12 crores, which has increased by approximately 22.97 % from Rs. 2,695.08 crores for the April-June 2020 quarter. The quarterly net profit in June 2021 was Rs. 645.87 crores, which has seen an increase by nearly 77.64 % from a net profit of Rs. 363.58 crores in June 2020. In June 2021, the reported operating profit was at Rs. 2,617.15 crores, which is also increased by 26.76% as compared to an operating profit of Rs. 2,064.73 crores for the quarter ending in June 2020. From Rs. 8.03 in June 2020, the EPS of Lupin Ltd has almost doubled and reached Rs. 14.13 per share in June 2021. LUPIN’s stock closed at Rs. 974.10 on 17th August’2021 (NSE) and has returned -8.29% in the last six months and -2.83% in the previous year.

Registered Address

Kalpataru Inspire 3rd Floor, Off Western Exp HW Santacruz-E, Mumbai, Maharashtra, 400055

Tel : 91-22-6640 2323
Email : investorservices:lupinpharma.com
Website : http://www.lupinworld.com; www.lupin.com
Registrar

Link Intime India Pvt Ltd

AGM Date (Month) : Aug
Face Value Equity Shares : 2
Market Lot Equity Shares : 1
BSE Code : 500257
NSE Code : LUPIN
Book Closure Date (Month) :
BSE Group : A
ISIN : INE326A01037

FAQ’s on Lupin Ltd Shares

You can buy Lupin Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Lupin Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of Mar 28, 2024 03:57 PM the closing price of Lupin Ltd was ₹ 1,616.80.

Market capitalization or market cap is determined by multiplying the current market price of a company’s shares with the total number of shares outstanding. As of Mar 28, 2024 03:57 PM, the market cap of Lupin Ltd stood at ₹ 73,617.27.

The latest PE ratio of Lupin Ltd as of Mar 28, 2024 03:57 PM is 40.66

The latest PB ratio of Lupin Ltd as of Mar 28, 2024 03:57 PM is 0.18

The 52-week high of Lupin Ltd share price is ₹ 1,704.25 while the 52-week low is ₹ 628.00

According to analyst recommendations, Lupin Ltd Share has a “Buy” rating for the long term.

Download Our

Download App
market app